Clinical trial for TB vaccine set

Scientists at Saint Louis University’s Center for Vaccine Development recently announced that they will conduct a clinical trial of an investigational vaccine for tuberculosis.

The vaccine, AERAS-422, is an updated version of the current TB vaccine that was developed nearly 90 years ago, reports.

"Not only is the start of the clinical trial of AERAS-422 another important benchmark in the search for more effective TB vaccines, it is also an opportunity to learn more about cellular immunity, which is less understood but crucially important in developing TB vaccines," Daniel Hoft, a researcher at SLU’s Center for Vaccine Development, said, according to

The modernized vaccine is designed to interrupt TB at all stages of infection and protect against all forms of the deadly infectious disease.

According to the World Health Organization, there were 9.4 million new TB cases reported in 2009, resulting in 1.7 million deaths. The vast majority of TB deaths occur in the developing world.

The research, funded by Aeras Global TB Vaccine Foundation, will also include a collaborative consortium to study new biomarker assays that better assess TB vaccine-induced immunity.

Other institutions collaborating on the initiative include Jenner Institute at the University of Oxford, the South African Tuberculosis Vaccine Initiative at the University of Cape Town, and the Albert Einstein College of Medicine at Yeshiva University.